Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 244,357 shares, a growth of 31.0% from the March 15th total of 186,549 shares. Currently, 2.4% of the company’s stock are sold short. Based on an average daily trading volume, of 369,603 shares, the short-interest ratio is presently 0.7 days.

Calidi Biotherapeutics Stock Down 0.8%

Shares of Calidi Biotherapeutics stock traded down $0.00 during midday trading on Friday, hitting $0.28. The company had a trading volume of 1,131,314 shares, compared to its average volume of 451,507. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 1.59. The stock has a market capitalization of $3.00 million, a P/E ratio of -0.04 and a beta of 1.42. The company has a 50 day moving average of $0.47 and a 200 day moving average of $1.05. Calidi Biotherapeutics has a 52-week low of $0.21 and a 52-week high of $19.20.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings results on Friday, March 27th. The company reported $0.45 earnings per share for the quarter. On average, equities analysts predict that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

Institutional Trading of Calidi Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in CLDI. DRW Securities LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter valued at $173,000. Virtu Financial LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter valued at $25,000. Warberg Asset Management LLC purchased a new stake in Calidi Biotherapeutics during the 3rd quarter valued at $28,000. Finally, Geode Capital Management LLC boosted its stake in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the last quarter. 12.53% of the stock is currently owned by hedge funds and other institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.